SAB Biotherapeutics (SABS) Interest Coverage Ratio Growth (1y) (2022 - 2026)
SAB Biotherapeutics (SABS) Interest Coverage Ratio Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | -60.44% |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - | - |
| 3 | Akari Therapeutics | 1,021.31 Bn | 1,021.31 Bn | - | -347.04% |
| 4 | BeOne Medicines | 467.89 Bn | 463.10 Bn | 1.35 Bn | 787.12% |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn | 53.59% |
| 6 | Regeneron Pharmaceuticals | 70.19 Bn | 61.44 Bn | 3.31 Bn | -32.04% |
| 7 | Belite Bio | 63.46 Bn | 63.46 Bn | - | - |
| 8 | Argenx Se | 55.64 Bn | 50.45 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | 1,378.45% |
| 10 | SAB Biotherapeutics | 190.13 Mn | 190.13 Mn | - | 98.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 98.24% |
| Dec 31, 2025 | 140.50% |
| Sep 30, 2025 | 59.84% |
| Jun 30, 2025 | 67.79% |
| Mar 31, 2025 | 14.48% |
| Dec 31, 2024 | -116.04% |
| Sep 30, 2024 | -256.46% |
| Jun 30, 2024 | -963.12% |
| Mar 31, 2024 | 23.09% |
| Dec 31, 2023 | 6,654.11% |
| Sep 30, 2023 | 44.91% |
| Jun 30, 2023 | -27.99% |
| Mar 31, 2023 | -190.86% |
| Dec 31, 2022 | 6.95% |
| Sep 30, 2022 | -57.59% |
| Jun 30, 2022 | 69.97% |
| Mar 31, 2022 | -810.13% |